CETINA PEREZ, LUCELY DEL CARMEN

CETINA PEREZ, LUCELY DEL CARMEN

INVESTIGACIÓN MÉDICA · Nivel 2

Desde 2001 es Investigador en Ciencias Médicas D en Instituto Nacional de Cancerología

Perfil académico

Nombre LUCELY DEL CARMEN CETINA PEREZ
Área MEDICINA Y CIENCIAS DE LA SALUD
Campo INVESTIGACIÓN MÉDICA
Disciplina INVESTIGACIÓN CLÍNICA
Especialidad ONCOLOGIA
CVU 123135
Institución
Dependencia DIVISION MEDICA
Entidad CIUDAD DE MEXICO
Nivel 2
Vigencia Inicio: 01/01/2022
Fin: 31/12/2026

Publicaciones ORCID

2025
The Evolving Role of Radiation Oncology in the Management of Uterine Cervical Carcinoma: A State-of-the-Art Review for Non-Radiation Oncologists Life
Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses Annals of Oncology
Machine and Deep Learning for the Diagnosis, Prognosis, and Treatment of Cervical Cancer: A Scoping Review Diagnostics
2024
Quality of life but not cachexia definitions are associated with overall survival in women with cervical cancer: a STROBE-compliant cohort study Japanese Journal of Clinical Oncology
Sociodemographic characteristics and their association with survival in women with cervical cancer BMC Cancer
Chemoradiotherapy treatment with gemcitabine improves renal function in locally advanced cervical cancer patients with renal dysfunction Current Problems in Cancer
2022
Impact of metabolic syndrome on the risk of endometrial cancer and the role of lifestyle in prevention Bosnian Journal of Basic Medical Sciences
2021
Validation of the QLQ-CX24 questionnaire for the assessment of quality of life in Mexican women with cervical cancer International Journal of Gynecological Cancer
2020
Body composition and nutritional status according to clinical stage in patients with locally advanced cervical cancer. European journal of clinical nutrition
Consensus Report on the Prevention, Diagnosis, and Treatment of Cervical Cancer - a Perspective from the Immune System Toward Immunotherapy.